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HIV, antiretroviral treatment,
hypertension, and stroke inMalawian adults
A case-control study
ABSTRACT
Objective: To investigate HIV, its treatment, and hypertension as stroke risk factors in Malawian
adults.
Methods: We performed a case-control study of 222 adults with acute stroke, confirmed by MRI
in 86%, and 503 population controls, frequency-matched for age, sex, and place of residence,
using Global Positioning System for random selection. Multivariate logistic regression models
were used for case-control comparisons.
Results: HIV infection (population attributable fraction [PAF] 15%) and hypertension (PAF 46%)
were strongly linked to stroke. HIV was the predominant risk factor for young stroke (#45 years),
with a prevalence of 67% and an adjusted odds ratio (aOR) (95% confidence interval) of 5.57
(2.43–12.8) (PAF 42%). There was an increased risk of a stroke in patients with untreated HIV
infection (aOR 4.48 [2.44–8.24], p , 0.001), but the highest risk was in the first 6 months after
starting antiretroviral therapy (ART) (aOR 15.6 [4.21–46.6], p , 0.001); this group had a lower
median CD41 T-lymphocyte count (92 vs 375 cells/mm3, p 5 0.004). In older participants (HIV
prevalence 17%), HIV was associated with stroke, but with a lower PAF than hypertension (5% vs
68%). There was no interaction between HIV and hypertension on stroke risk.
Conclusions: In a population with high HIV prevalence, where stroke incidence is increasing, we
have shown that HIV is an important risk factor. Early ART use in immunosuppressed patients
poses an additional and potentially treatable stroke risk. Immune reconstitution inflammatory syn-
drome may be contributing to the disease mechanisms. Neurology® 2016;86:324–333
GLOSSARY
3TC 5 lamivudine; aOR 5 adjusted odds ratio; ART 5 antiretroviral therapy; AZT 5 zidovudine; d4T 5 stavudine; IRIS 5
immune reconstitution inflammatory syndrome;NIHSS5NIH Stroke Scale;NVP5 nevirapine; PAF5 population attributable
fraction.
Across most of sub-Saharan Africa, the incidence of stroke is increasing.1 Much of this has been
attributed to hypertension, but in countries such as Malawi and South Africa, a substantial
proportion of stroke patients are young, and have a low prevalence of established risk factors
such as hypertension, suggesting other factors may be important.2,3
It is postulated that HIV also predisposes to stroke.4 The virus may cause stroke directly
(for example, through HIV-associated vasculopathy) or indirectly (through opportunistic
infections).4 In addition, some drugs used in antiretroviral therapy (ART) for HIV are
associated with metabolic syndromes, therefore potentially increasing stroke risk with pro-
longed use.5
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Although several studies have looked at
HIV and stroke, the effects of HIV infection,
especially the role of ART, and its interaction
with prevalent risk factors such as hyperten-
sion, particularly in African populations,
remain uncertain.4 We therefore conducted a
case-control study with prospective recruit-
ment of cases and community controls, exam-
ining the role of HIV, its treatment, and its
interaction with hypertension as risk factors
for stroke in Malawian adults.
METHODS Study site. Malawi is located in southern Africa;
the commercial capital is Blantyre. It is the 7th poorest country in
the world. Life expectancy is 55 years. The national HIV preva-
lence is 10.3%, higher in comparison with other sub-Saharan
African countries (5% in Tanzania [East Africa] and 3.2% in
Nigeria [West Africa]).
Queen Elizabeth Central Hospital is the main hospital for the
Blantyre district, as well as being the referral hospital for the
southern region of Malawi. It has an estimated adult HIV preva-
lence of 18.5%.6 Approximately 1 million people reside in the
Blantyre district.
Study design. Adult residents (age $18 years) of the Blantyre
district who presented to the hospital within 7 days of the onset
of symptoms who met the WHO case definition of stroke7
were recruited as study cases between February 2011 and April
2012. Participants were initially screened for eligibility by the
study nurse using a standardized questionnaire, before a physi-
cian’s review. Scans were performed on a GE (Milwaukee, WI)
0.35T Signa Ovation Excite MRI scanner within 7 days of
admission. The images were reported by a local radiologist
and subsequently reviewed by a neuroradiologist and an infec-
tious diseases radiologist. Patients with recurrent stroke were
eligible for inclusion, provided they had not already partici-
pated in the study.
Population controls were recruited from the local popula-
tion in predefined residential neighborhoods within the district
of Blantyre between January and November 2012. Two com-
munity controls were selected at random for every case, using a
modification of a previously described approach that selected
an age/sex frequency-matched random sample of the popula-
tion, with a geographical distribution in proportion to the pop-
ulation density.8 The distribution of age (5-year age bands),
sex, and place of residence of the first 100 cases was used to
guide stratified recruitment, frequency-matching for these fac-
tors (figure 1). Random starting points and direction were
overlaid onto high-resolution satellite maps (March 2010 im-
ages: GeoEye-1/Eurimage SpA) using Google Earth pro soft-
ware. Global Positioning System coordinates from the first
dwelling intersected by any given randomly generated vector
were recorded.
Procedures. For cases, the clinical subtype and severity of stroke
were recorded using the Oxfordshire Community Stroke Project
classification and NIH Stroke Scale (NIHSS) criteria.9,10 Ischemic
and hemorrhagic stroke types were determined by MRI brain
scan findings.
Demographic information, nonmodifiable risk factors (age,
sex, socioeconomic status, and family history of stroke), and
modifiable risk factors (HIV infection, HIV treatment and its
duration, hypertension, diabetes, hypercholesterolemia, acute
infection, smoking, alcohol use, pregnancy, and substance use
[cannabis, cocaine, and heroin]) were recorded from cases and
controls. Socioeconomic status was defined by education, occupa-
tion, place of residence, and housing type.11 Examination was
performed to determine the waist-hip ratio, a marker of abdom-
inal obesity, and blood pressure.12 Cases and controls were
screened for diabetes, hypercholesterolemia, and HIV infection;
if positive, the CD41 count (CD41 T-lymphocyte cell count; BD
FACS Count System, Becton Dickinson, San Jose, CA) and HIV
viral load (Hologic Commercial Kits, Sussex, UK) were
measured.
Definition of criteria used. Stroke severity was classified as
nonsevere or severe using the NIHSS.9 HIV diagnosis was made
from 2 rapid tests in parallel (Unigold, Trinity Biotech, Wicklow,
Ireland; Determine, Alere Medical, Philadelphia, PA; SD Bioline,
Standard Diagnostics, Gyeonggi-do, Korea, was used as a
tiebreaker). CD41 count was classified as ,200 cells/mm3,
200–349 cells/mm3, 350–500 cells/mm3, or .500 cells/mm3.13
To explore the possible role of immune reconstitution syndrome,
a cutoff of 6 months was used to classify the duration of ART.14
The timing of ART was cross-checked with an electronic medical
records system at Queen Elizabeth Central Hospital.15 The
limit of sensitivity for HIV detection was ,30 copies/mL.
Blood pressure was recorded at day 0. Three sequential
readings were recorded and an average taken. Hypertension
was defined as a blood pressure .140/90 mm Hg or use of
antihypertensive medication.16 Diabetes mellitus was defined
as a nonfasting blood glucose of $11.1 mmol/L or use of
glucose-lowering medication.17 Patients were classified as having
hypercholesterolemia if they used lipid-lowering medication or
had a nonfasting serum cholesterol concentration $6.2
mmol/L.18 Waist-hip ratio was calculated as tertiles from the
control cohort.12 Recent infection was defined as a fever or
treated infection within 14 days of the stroke (cases) or
interview (controls).19
Standard protocol approvals, registrations, and patient
consents. The study was approved by the Liverpool School of
Tropical Medicine, United Kingdom, and the College of Medi-
cine Research Ethics Committee, University of Malawi. All par-
ticipants or guardians gave written informed consent.
Individuals with newly diagnosed risk factors in the community
were referred to an appropriate outpatient clinic.
Statistical analysis. The prevalence of potential risk factors
was compared between cases and controls. Continuous varia-
bles were summarized using means and medians and compared
using a Student independent-samples t test or Mann-Whitney
U test as appropriate for the distribution properties of each
variable.
A sample size of 750 individuals (250 case-control sets, each
with 1 case and 2 controls) was estimated as providing 95%
power to detect an odds ratio of 2 or greater for HIV prevalence,
assuming that 18% of the control individuals would be found to
have HIV infection.6
A conceptual framework was used to divide all other poten-
tial risk factors into proximal determinants that have direct ef-
fects on stroke and distal determinants that have indirect
effects. Distal determinants were defined as age, sex, family his-
tory, socioeconomic status, and season. Proximal determinants
were HIV status (also expanded or substituted by HIV treat-
ment status and level of immunosuppression in some of the
analysis), hypertension, diabetes, hypercholesterolemia, acute
infection, abdominal obesity, and alcohol and substance
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use. The proximal determinants were evaluated individually
(univariate model approach) after adjustment for age, sex,
and urban location (variables used for frequency matching).
Unconditional multivariate logistic regression models were
then constructed based on this conceptual framework describ-
ing the hierarchical relationships among the matching, proxi-
mal, and distal determinants. The role of each distal
determinant was further assessed by comparing the model with
or without using the likelihood ratio test, subtracting variables
from the model that were not significant.20 This was repeated
after stratifying by age and type of stroke. Missing observations
were included in the analysis by creating missing value catego-
ries. The findings from these models are reported as odds ratios
with their 95% confidence intervals. All reported p values were
2-sided with a conventional 5% a level. Population attribut-
able fraction (PAF) was calculated using methods defined by
Greenland and Drescher.21 Interaction between the risk factors
for stroke was assessed on an additive and multiplicative scale.
Interaction on the additive scale was assessed by calculating the
relative excess risk caused by interaction.22,23 Interaction on the
multiplicative scale was assessed by comparing multiplicative
models with and without an interaction term using the log-
likelihood ratio test. The data were analyzed with STATA ver-
sion 11.2.
RESULTS We screened 553 patients with suspected
stroke and 1,686 households, to obtain 222 stroke
cases and 503 controls (figure 1). An MRI brain scan
was performed in 190/222 (86%) cases; 149 (78%)
had findings consistent with an ischemic stroke and
41 (22%) a hemorrhagic stroke. Ischemic stroke
Figure 1 Flow diagram of case and control recruitment
*Control selection: dwellings were visited and all eligible potential control participants were identified. If no one was home,
dwellings were visited up to 3 times. Where multiple individuals were eligible, the oldest individual was recruited. If no
eligible individual was identified, the next dwelling intersected was visited. Recruitment continued in each residential neigh-
borhood until the prespecified numbers of individuals in each age and sex category had been met. QECH5Queen Elizabeth
Central Hospital.
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subtype and severity are summarized in table 1; in the
HIV population, the subtype and severity were sim-
ilar in proportions to the HIV-negative cohort.
Cases and controls were well matched for age, sex,
socioeconomic status, and season of admission to the
study (table 1). A sensitivity analysis was performed,
excluding those without MRI (n 5 32); the trends
were consistent with those reported below.
HIV and ART. Stroke was strongly associated with
HIV infection (adjusted odds ratio [aOR] 3.28).
Timing of ART was important: having started ART
in the previous 6 months (aOR 15.6) posed the great-
est risk of stroke (table 2).
The association between HIV infection and
stroke was more evident in younger individuals
(#45 years) (PAF 42%) compared to older individ-
uals (PAF 6%; table 3). Although the prevalence of
HIV was lower in the older participants (67% vs
18%), there was still a strong association with
untreated HIV infection and with recently initiated
ART (table 3). HIV infection was significantly asso-
ciated with ischemic stroke (table e-1 on the
Neurology® Web site at Neurology.org).
Thirty-one out of 69 (45%) cases and 21/95
(22%) controls met the definition of AIDS. We per-
formed a subgroup analysis in the HIV-positive pop-
ulation. The reference group used was the HIV
untreated cohort. We further subdivided the $6
months treatment group by the presence or absence
of detectable HIV virus. We found that lower CD41
count was a major risk factor for HIV-related stroke
risk (figure 2). Furthermore, the CD41 count was
significantly lower among those starting ART in the
first 6 months (92 vs 375 cells/mm3; p 5 0.004)
(table e-2). There was no association with HIV viral
load and stroke (table e-2).
First-line therapy for HIV infection was stavudine
(d4T), lamivudine (3TC), and nevirapine (NVP) and
alternative first line was zidovudine (AZT), 3TC, and
NVP. The prevalence of the stavudine-based regimen
in cases and controls was 23 and 13 (64% and 36%;
p , 0.001), respectively. No patients were on prote-
ase inhibitors.
Hypertension. Hypertension was strongly associated
with stroke overall (aOR 5.01; table 2). The risk
was stronger for hemorrhagic stroke (aOR 9.35; table
e-1). The effect of hypertension was more evident in
those .45 years old than in those #45 years old
(table 3). Of the 438 participants with hypertension,
only 118 (27%) were on treatment.
Interaction of HIV and hypertension. The combined
aOR between HIV infection and hypertension for
stroke was 13.63 (6.30, 29.45; table e-3), with no evi-
dence of effect modification between these 2 risk fac-
tors and stroke risk (table e-3).
Other vascular risk factors. Diabetes was associated
with a small proportion of strokes overall (aOR
3.41; table 2). Smoking (PAF 6%) and recent infec-
tion (PAF 3%) were also associated with stroke
(table 2). There was no significant association
between hypercholesterolemia and stroke (tables 2
and 3 and e-1); all participants were untreated.
Table 1 Baseline characteristics of cases and controls
Cases, all stroke
(WHO defined) (n 5 222),
n (%)
Controlsa
(n 5 503),
n (%)
Median age, y (IQR) 60 (42, 70) 57 (42, 67)
Male sex 107 (48) 249 (50)
Urban location 143 (64) 343 (68)
HIV prevalence 69 (31) 95 (19)
Employed 69 (31) 163 (32)
Highest education
Less than primary school 136 (61) 309 (61)
Primary education 53 (24) 125 (25)
Secondary education 25 (11) 51 (10)
Tertiary 4 (2) 18 (4)
Type of housing
Employer’s accommodation 0 8 (1)
House/flat 23 (10) 48 (10)
Shack 189 (85) 447 (89)
Family history of stroke 37 (17) 67 (13)
Season
January–March 56 (25) 137 (27)
April–June 54 (24) 120 (24)
July–September 64 (29) 129 (26)
October–December 48 (22) 117 (23)
Subtype of ischemic stroke (n 5 149)b
Total anterior circulation infarct 37 (25) NP
Partial anterior circulation infarct 46 (31)
Posterior circulation infarct 6 (4)
Lacunar infarct 60 (40)
Severity of ischemic stroke (n 5 149)b,c
Nonsevere (<14) 93 (62) NP
Severe (‡14) 55 (37)
Abbreviations: IQR 5 interquartile range; NP 5 not performed.
Data were missing for the following cases and controls: 1 HIV prevalence, 4 education, 10
housing type, and 1 stroke severity.
a The distribution of age (5-year age bands), sex, and place of residence of the first 100
cases was used to guide stratified recruitment of controls, frequency-matching for these
factors.
b The following proportions were found in the HIV-positive population: total anterior
circulation (18/69; 26%), partial anterior circulation (21/69; 30%), lacunar circulation
(27/69; 39%), and posterior circulation (3/69; 4%), and severity (mild–moderate [46/69;
67%], severe [23/69; 33%]). Subtype of stroke was defined by Oxfordshire Community
Stroke classification.
c Severity of stroke was defined by the NIH Stroke Scale.
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Table 2 Univariate and multivariate analysis for modifiable risk factors in all patients with stroke
Prevalence All stroke
Cases (n 5 222), n (%) Controls (n 5 5 03), n (%) Univariatea OR 95% CI; p value Multivariate ORb 95% CI; p value PAFc (95% CI)
HIV-positive 69 (31) 95 (19) 2.33 1.58 to 3.48; ,0.001 3.28 2.05 to 5.25; ,0.001 15 (9 to 21)
HIV treatment status
HIV-negative 151 (68) 408 (81) 1 1
Untreated 38 (17) 47 (9) 2.85 1.70 to 4.77; ,0.001 4.48 2.44 to 8.24; ,0.001
Had ART for <6 months 16 (7) 7 (1) 8.86 3.42 to 22.9; ,0.001 15.6 4.21 to 46.6; ,0.001
Had ART for ‡6 months 14 (6) 38 (8) 1.14 0.59 to 2.02; 0.249 1.49 0.72 to 3.07; 0.280 —
Hypertension 165 (74) 273 (54) 3.13 2.10 to 4.66; ,0.001 5.01 3.02 to 8.29; ,0.001 46 (35 to 56)
Other vascular risk factors
Diabetes 19 (9) 11 (2) 4.42 2.05 to 9.53; ,0.001 3.41 1.45 to 8.01; 0.005 3 (1 to 6)
Hypercholesterolemia 18 (8) 28 (6) 1.69 0.90 to 3.15; 0.102 1.54 0.77 to 3.08; 0.219 2 (21 to 5)
Recent infection 25 (11) 37 (7) 1.67 0.98 to 2.87; 0.062 1.38 1.45 to 8.01; 0.005 3 (0.3 to 5)
Current smoker 41 (18) 63 (13) 1.66 1.05 to 2.63; 0.029 2.36 1.34 to 4.13; 0.003 6 (2 to 11)
Cannabis used 6 (3) 7 (1) 2.03 0.66 to 6.23; 0.215 1.23 0.72 to 2.12; 0.447 0.5 (20.8 to 2)
Current alcohol drinker 34 (15) 92 (18) 0.79 0.50 to 1.25; 0.322 0.73 0.52 to 1.02; 0.067 24 (28 to 0.2)
Pregnancy 4 (2) 8 (2) 1.02 0.29 to 3.64; 0.965 1.67 0.78 to 3.62; 0.194 1 (0.1 to 2)
Abdominal obesitye
T1 49 (22) 150 (30) 1 1
T2 75 (34) 211 (42) 1.10 0.72 to 1.67; 0.661 0.83 0.51 to 1.35; 0.459 26 (217 to 3)
T3 93 (42) 141 (28) 2.07 1.35 to 3.16; 0.001 1.36 0.84 to 2.20; 0.208 5 (25 to 14)
Abbreviations: ART 5 antiretroviral therapy; CI 5 confidence interval; OR 5 odds ratio; PAF 5 population attributable fraction.
Data were missing for the following cases and controls: 1 HIV status, 6 HIV treatment status, 24 hypercholesterolemia, 9 recent infection, 5 cannabis use, 13 alcohol use, 3 pregnancy, and 6 abdominal obesity;
these individuals were included in the analysis by creating missing value categories.
aAdjusted for frequency-matched variables: age, sex, and urban location.
bAdjusted for hypertension, recent infection, abdominal obesity, HIV-positive status, smoking, current alcohol use, hypercholesterolemia, cannabis use, age, sex, type of housing, and urban location.
cNegative PAF was considered protective. For variables with more than 2 categories (i.e., HIV status and waist-hip ratio), PAF was calculated from the reference category (e.g., T1 vs T2 and T1 vs T3).
d There was no exposure to other substance use such as heroin or cocaine.
eAbdominal obesity (waist-hip ratio) tertiles (T) calculated as tertiles from the control cohort. Cutoffs of 0.86 and 0.9 were used to divide participants into thirds.
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Table 3 Multivariate analysis for modifiable risk factors in younger and older stroke patients
Prevalence Younger (£45 years) strokea Prevalence Older (>45 years) strokeb
Cases
(n 5 61),
n (%)
Controls
(n 5 151),
n (%)
Multivariate,c
OR
95% CI;
p value
PAF,d
(95% CI)
Cases
(n 5 16),
n (%)
Controls
(n 5 352),
n (%)
Multivariate,e
OR
95% CI;
p value
PAF,d
(95% CI)
HIV-positive 41 (67) 41 (31) 5.57 2.43 to 12.8; ,0.001 42 (20 to 58) 28 (18) 48 (14) 2.10 1.10 to 4.01; 0.024 6 (0.3 to 10)
HIV treatment status
HIV-negative 20 (33) 104 (69) 1 131 (81) 304 (86) 1
Untreated 24 (39) 29 (19) 5.04 1.99 to 12.8; 0.001 14 (9) 18 (5) 2.93 1.18 to 7.27; 0.020
Had ART for <6 months 12 (20) 4 (3) 22.8 4.91 to 106; ,0.001 4 (2) 3 (1) 15.9 2.03 to 124; 0.008
Had ART for ‡6 months 5 (8) 13 (9) 3.27 0.88 to 12.1; 0.077 9 (6) 25 (7) 1.31 0.52 to 3.28; 0.591
Hypertension 21 (34) 46 (31) 1.92 0.84 to 4.36; 0.119 11 (24 to 24) 144 (89) 227 (64) 8.57 4.31 to 17.0; ,0.001 68 (52 to 79)
Other vascular risk factors
Diabetes 1 (2) 1 (1) 4.83 0.23 to 100; 0.308 1 (22 to 4) 18 (11) 10 (2) 2.79 1.17 to 6.65; 0.021 4 (1 to 7)
Hypercholesterolemia 4 (7) 3 (2) 4.66 0.71 to 30.8; 0.110 3 (21 to 7) 14 (9) 25 (7) 1.32 0.62 to 2.80; 0.465 1 (23 to 4)
Recent infection 14 (23) 11 (7) 2.87 0.98 to 8.42; 0.054 9 (21 to 17) 11 (7) 26 (7) 1.36 0.97 to 1.91; 0.077 2 (0.2 to 5)
Current smoker 8 (13) 16 (11) 0.73 0.18 to 2.87; 0.655 22 (211 to 6) 33 (21) 47 (13) 2.65 1.40 to 5.03; 0.003 8 (3 to 13)
Abdominal obesityf
T1 13 (21) 63 (42) 1 36 (22) 87 (25) 1
T2 26 (43) 60 (40) 1.29 0.52 to 3.21; 0.579 3 (218 to 22) 49 (30) 151 (43) 0.59 0.33 to 1.05; 0.072 213 (225 to 21)
T3 21 (34) 28 (19) 3.05 1.14 to 8.18; 0.026 15 (20.6 to 28) 72 (45) 113 (32) 1.04 0.59 to 1.83; 0.886 21 (214 to 11)
Abbreviations: ART 5 antiretroviral therapy; CI 5 confidence interval; OR 5 odds ratio; PAF 5 population attributable fraction.
a For the younger stroke patient analysis, data were missing in the following cases and controls: 1 HIV treatment status, 4 hypercholesterolemia, 2 cannabis use, 3 alcohol use, and 1 abdominal obesity; these
individuals were included in the analysis by creating missing value categories.
b For the older stroke patient analysis, data were missing in the following cases and controls: 1 HIV-positive status, 5 HIV treatment status, 20 hypercholesterolemia, 9 recent infections, 3 cannabis use, 10 alcohol
use, 3 pregnancy, and 5 abdominal obesity. Missing observations were included in the analysis by creating missing value categories.
cAdjusted for hypertension, recent infection, abdominal obesity, HIV-positive status, smoking, current alcohol use, hypercholesterolemia, cannabis use, age, sex, and urban location.
dNegative PAF was considered protective. For variables with more than 2 categories (i.e., waist-hip ratio), PAF was calculated from the reference category (e.g., T1 vs T2 and T1 vs T3).
eAdjusted for hypertension, recent infection, abdominal obesity, HIV-positive status, smoking, current alcohol use, hypercholesterolemia, cannabis use, age, sex, type of housing, and urban location.
f Abdominal obesity (waist-hip ratio) tertiles (T) calculated as tertiles from the control cohort. Cutoffs of 0.86 and 0.9 were used to divide participants into thirds.
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Cannabis was not a risk factor for stroke. None of our
study participants used cocaine or amphetamines.
DISCUSSION This case-control study showed that
HIV infection is an independent risk factor for
stroke in Malawian adults. Notably, we also found
that for patients who had started standard HIV
treatment in the previous 6 months, the risk of
stroke was even higher (aOR 15.6). Although
hypertension was the leading risk factor in this
population overall (PAF 46%), HIV infection and
its treatment were the second most important risk
factors (PAF 15%), and had the highest population
attributable risk in younger patients (PAF 42%).
Most previous studies of HIV infection and stroke
have been retrospective,4 but one recent prospective
study reported the importance of HIV as a risk factor
in East Africa24; however, this was limited by a low
number of patients having brain imaging to confirm
the stroke, and a low number having HIV testing,25
both reducing the power to investigate any relation-
ship among the nature of stroke, timing of ART, and
the interaction between hypertension and HIV infec-
tion. Our study, with well-defined cases, carefully
Figure 2 HIV treatment status, viral load, CD41 count, and stroke risk
(A) Multivariate analysis of HIV treatment status, CD41 count, and stroke risk, represented graphically. (B) Univariate and multivariate analysis of HIV
treatment status, CD41 count, and stroke risk. Explores the association of HIV treatment status and stroke risk after adjusting for immunosuppression.
*Adjusted for frequency-matched variables: age, sex, and urban location. **Adjusted for hypertension, recent infection, abdominal obesity, HIV treatment
status, smoking, current alcohol use, CD41 T-lymphocyte count, hypercholesterolemia, cannabis use, age, sex, type of housing, and urban location.
†A combined p value was calculated using a likelihood ratio test for variables with .2 categories. Data were missing for the following cases and controls:
13 HIV treatment status (including HIV viral load data), 12 CD41 T-lymphocyte cell count, 2 recent infection, 2 waist-hip ratio, 1 alcohol, 8 pregnant,
1 substance use. Missing observations were included in the analysis by creating missing value categories.
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selected population controls, and 99% ascertainment
of HIV status, provides the clearest evidence yet that
HIV is indeed an important risk factor for stroke. We
found that HIV infection was associated with ische-
mic but not hemorrhagic stroke. A variety of mech-
anisms might be implicated: HIV infection is known
to cause endothelial dysfunction, resulting in a vascu-
lopathy that can manifest in several forms (e.g., accel-
erated atherosclerosis and small vessel disease); in
addition, opportunistic infections such as VZV,
which are more common in HIV infection, can also
disrupt the vascular endothelium.4 Further evaluation
of infections is beyond the scope of this article.
Importantly, we found that the risk of stroke was
much higher in the first 6 months after starting ART.
This clinical deterioration suggests a contribution to
risk from an immune reconstitution inflammatory
syndrome (IRIS)–like process.14
In HIV infection, IRIS is thought to be the conse-
quence of an overwhelming pathogen-specific, cell-
mediated immune response, arising either through
unmasking of an occult infection or a paradoxical
deterioration following HIV treatment.14 In the lat-
ter, the recovering immune response is thought to
target persisting pathogen-derived antigens or, possi-
bly, self-antigens, causing tissue damage.14 In the case
of stroke, this immune process could target antigens
arising from HIV-mediated tissue damage or HIV
itself. We showed that stroke risk associated with
ART in the first 6 months (and in the untreated
cohort) was associated with immunosuppression. In
contrast, those on longer-term treatment had a much
higher CD41 count, possibly explaining the reduced
stroke risk in this group. Immunosuppression is a
recognized risk factor for IRIS and thus a plausible
mechanism of stroke among those starting ART.
There is also the possibility of other simultaneous
or independent mechanisms (beyond immunosup-
pression) occurring during this phase, such as stavu-
dine toxicity and poor ART adherence; however, this
needs to be further characterized.26,27 Because our
numbers were limited in the early ART cohort, the
results should be interpreted with caution. However,
insights from the large prospective Data Collection
on Adverse Events of Anti-HIV Drugs (D:A:D) study
support our findings.28 In this study, there was an
increased risk of cardiovascular and cerebrovascular
disease events for 4 years after starting ART; although
it was not highlighted at the time, the data indicate
the rate of vascular events was greatest in the first year
of follow-up, consistent with a temporal relationship
to initiation of ART (figure e-1).28
Higher CD41 counts (a function of ART) were
associated with reduced stroke risk, suggesting that
HIV treatment is indeed beneficial overall. However,
the stroke risk in the immunosuppressed early ART
group needs further investigation; a better under-
standing may point to empirical antimicrobial
treatment of occult infection or initiation of anti-
inflammatory agents at the time of starting ART.
There was no statistically significant additive or
multiplicative interaction between hypertension and
HIV infection on stroke risk. Although our study
was underpowered to fully address this, our findings
are consistent with those of a large US cohort study
investigating interactions among HIV, hypertension,
and cardiovascular disease: in individuals with acute
myocardial infarction, no such interaction was seen.29
In Malawi, we found hypertension was an important
risk factor in older, but not younger, stroke patients.
This finding is different from the multinational inter-
stroke study, which attributed most young strokes in
low- and middle-income countries to hypertension;
in that study, only one fifth of the patients were from
sub-Saharan Africa, and most of these were from
wealthier African countries where hypertension, dia-
betes, and hypercholesterolemia are likely to occur
with higher prevalence than in Malawi.12,30,31
Our study had several limitations. Recall bias can-
not be excluded, but the prospective recruitment of
cases and objective measurement of the important
risk factors has considerably reduced this possibility.
Although blood pressure measurement in the acute
phase of a stroke could potentially overestimate stroke
risk, our findings were consistent with a stroke study
in East Africa; this study measured blood pressure on
day 7.24 The low prevalence of high cholesterol in
Malawi or not measuring the more sensitive low-
density lipoprotein could explain the lack of associa-
tion between cholesterol and stroke in our study.30
The absence of an association between HIV and hem-
orrhagic stroke could be due to insufficient power.
Because the hospital prevalence of HIV infection
was much higher (70%)32 than in the community
(18%), using hospital controls would have distorted
the stroke risk seen with HIV infection. We therefore
opted for population controls to avoid this bias. Argu-
ably, by using population controls, the risk seen with
hypertension could have been overestimated but the
result of this risk factor was consistent with those
from similar settings.24 In the community, the refusal
rate for entering the study was low (14%), minimizing
selection bias. The HIV prevalence in our control
cohort was consistent with a previous study in this
setting,6 supporting the validity of our control selec-
tion process. Because age, sex, and urban location are
important confounders of stroke and HIV infection,
we adopted a stratified approach for these variables.
This was especially important in our setting because
the age of stroke patients was considerably greater
than the median age of Blantyre residents. Although
this stratification minimized selection bias, it limited
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our ability to comment on these factors or their effect
modification on stroke risk. The PAF was not affected
by underlying age structure and the formula can be
calculated using the distribution of risk factors among
the cases alone, independent of the control popula-
tion.33 Hospital recruitment of cases could have led to
selection bias, missing out on milder strokes or pa-
tients who may have died in the community.34 How-
ever, a study in East Africa used a hot pursuit
approach and verbal autopsy to capture these cases;
they described similar risk factor profiles to ours.
Therefore, we suspect that such potential biases are
unlikely to have affected our risk factor analysis.24
HIV infection is an important risk factor for stroke
in Malawi, especially ischemic stroke in young peo-
ple. Importantly, there was a high risk of stroke in
the first 6 months after starting ART; this was largely
related to immunosuppression. While ART is neces-
sary for improved HIV related outcomes overall, the
association between early ART use and stroke events
poses an additional (and potentially treatable) risk.
How to address this is something that the research
community will need to consider in sub-Saharan Afri-
ca and beyond.
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